Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, and Metsera, Inc. ("Metsera"), a clinical-stage biopharmaceutical company accelerating the ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

Amneal Pharmaceuticals (AMRX) and Metsera have entered into a collaboration agreement to enable the efficient development and ...

The race to supply obesity drugs is so competitive that one early-stage startup is already striking a deal for commercial ...

Delilah Alvarado Obesity drug startup Metsera said Tuesday it has signed a deal with manufacturing firm Amneal ...

Metsera, a biotech focused on obesity treatments, came out of stealth only this year, and its lead drug is still in early ...

Breast cancer remains the most common cancer among women in Canada, but early detection can save lives. PocketHealth is ...

MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria and ...

Obesity startup Metsera is getting a new manufacturing partner and a new CEO. On Tuesday, the well-funded startup announced ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body weight compared to baseline at 36 days. While the biotech has yet to ...

Sept 23 (Reuters) - Amneal Pharmaceuticals (AMRX.O), opens new tab has sued Colorado in an effort to block a state law requiring it to provide free generic EpiPens to pharmacies. In a complaint ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a prominent player in the specialty pharmaceuticals sector, has been making waves in the market with its recent performance and strategic initiatives ...